Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia

被引:62
作者
Leibovitz, E
Hazanov, N
Zimlichman, R
Shargorodsky, M
Gavish, D [1 ]
机构
[1] Wolfson Med Ctr, Dept Internal Med A, IL-58100 Tel Giborim, Holon, Israel
[2] Wolfson Med Ctr, Inst Physiol Hyg, Tel Giborim, Holon, Israel
关键词
arterial compliance; hypercholesterolemia; statins; blood pressure;
D O I
10.1016/S0895-7061(01)02210-5
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: We studied the effect of atorvastatin on arterial compliance in patients with severe hypercholesterolemia, Methods: Seventeen patients, with low-density lipoprotein cholesterol levels above 170 mg/dL, were included in the study, none of whomever received hypolipidemic medication, or had other risk factors. Patients were followed for five visits, every 4 weeks. Results: After 20 weeks. of treatment, lipid profile improved significantly. Large artery elasticity index did not change significantly, but small artery elasticity index increased by 21% (4.6 +/- 0.5 to 5.6 +/- 0.9, P < .01). Although none of our patients suffered from hypertension, both systolic and diastolic blood pressure (BP) decreased significantly (6 mm Hg and 3 mm Hg, respectively). Conclusions: We conclude that atorvastatin improves the elasticity of small arteries and reduces systolic and diastolic BP in patients with severe hypercholesterolemia. (C) 2001 American Journal of Hypertension, Ltd.
引用
收藏
页码:1096 / 1098
页数:3
相关论文
共 14 条
[1]  
Cameron J D, 1996, J Cardiovasc Risk, V3, P495, DOI 10.1097/00043798-199612000-00003
[2]  
Cameron JD, 1995, J HYPERTENS, V13, P1718
[3]   Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease [J].
Cohn, JN .
PROGRESS IN CARDIOVASCULAR DISEASES, 1999, 41 (06) :441-450
[4]  
Cohn JN, 1999, J HYPERTENS, V17, pS41
[5]   NONINVASIVE PULSE-WAVE ANALYSIS FOR THE EARLY DETECTION OF VASCULAR-DISEASE [J].
COHN, JN ;
FINKELSTEIN, S ;
MCVEIGH, G ;
MORGAN, D ;
LEMAY, L ;
ROBINSON, J ;
MOCK, J .
HYPERTENSION, 1995, 26 (03) :503-508
[6]   Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase [J].
Endres, M ;
Laufs, U ;
Huang, ZH ;
Nakamura, T ;
Huang, P ;
Moskowitz, MA ;
Liao, JK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8880-8885
[7]  
Feron O, 2001, CIRCULATION, V103, P113
[8]   The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. [J].
Kureishi, Y ;
Luo, ZY ;
Shiojima, I ;
Bialik, A ;
Fulton, D ;
Lefer, DJ ;
Sessa, WC ;
Walsh, K .
NATURE MEDICINE, 2000, 6 (09) :1004-1010
[9]  
Packard CJ, 1998, CIRCULATION, V97, P1440
[10]   Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins [J].
Rauch, U ;
Osende, JI ;
Chesebro, JH ;
Fuster, V ;
Vorchheimer, DA ;
Harris, K ;
Harris, P ;
Sandler, DA ;
Fallon, JT ;
Jayaraman, S ;
Badimon, JJ .
ATHEROSCLEROSIS, 2000, 153 (01) :181-189